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Core shell lipid-polymer hybrid 
nanoparticles with combined 
docetaxel and molecular targeted 
therapy for the treatment of 
metastatic prostate cancer
Qi Wang1, Heba Alshaker1,2, Torsten Böhler3, Shyam Srivats4, Yimin Chao  5, Colin Cooper1 & 
Dmitri Pchejetski1
Many prostate cancers relapse after initial chemotherapy treatment. Combining molecular and 
chemotherapy together with encapsulation of drugs in nanocarriers provides effective drug delivery and 
toxicity reduction. We developed core shell lipid-polymer hybrid nanoparticles (CSLPHNPs) with poly 
(lactic-co-glycolic acid) (PLGA) core and lipid layer containing docetaxel and clinically used inhibitor of 
sphingosine kinase 1 (SK1) FTY720 (fingolimod). We show for the first time that FTY720 (both free and 
in CSLPHNPs) re-sensitizes castrate resistant prostate cancer cells and tumors to docetaxel, allowing a 
four-fold reduction in effective dose. Our CSLPHNPs showed high serum stability and a long shelf life. 
CSLPHNPs demonstrated a steady uptake by tumor cells, sustained intracellular drug release and in 
vitro efficacy superior to free therapies. In a mouse model of human prostate cancer, CSLPHNPs showed 
excellent tumor targeting and significantly lower side effects compared to free drugs, importantly, 
reversing lymphopenia induced by FTY720. Overall, we demonstrate that nanoparticle encapsulation 
can improve targeting, provide low off-target toxicity and most importantly reduce FTY720-induced 
lymphopenia, suggesting its potential use in clinical cancer treatment.
In the Western world, prostate cancer is now the most commonly diagnosed noncutaneous cancer in men and 
the second leading cause of cancer mortality1. Hormone therapy is offered for patients with locally advanced or 
metastatic disease, but many tumors relapse. Docetaxel is a first line chemotherapy offered to these patients, how-
ever, it only extends survival for a median period of less than three months2. Recently published GETUG-AFU 
153 and STAMPEDE4 clinical trials revived the interest in docetaxel showing that its early administration together 
with androgen deprivation therapy could largely improve the overall survival. New ways of re-sensitizing prostate 
cancer to docetaxel would present a significant therapeutic benefit.
Sphingosine kinase 1 (SK1) is a proto-oncogenic enzyme that is highly expressed in human prostate tumors5 
and correlates with prostate cancer cell chemoresistance6. Silencing SK1 sensitizes prostate tumors to docetaxel 
chemotherapy7, 8 and can potentially provide a new chemotherapeutic modality for patients with prostate cancer 
resistant to docetaxel. FTY720 is a functional antagonist of sphingosine-1-phosphate (S1P) receptors and an 
inhibitor of SK19. It is clinically used to treat multiple sclerosis10 by inducing lymphopenia and T-cell sequestra-
tion to lymph nodes9, which is the main obstacle for FTY720 use in cancer patients. The main adverse effects of 
docetaxel chemotherapy are non-hematologic toxicities and febrile neutropenia11.
Encapsulation of drugs in nanocarriers that target cancer cells is an effective method of co-delivery of drug 
combinations and toxicity reduction. Liposomes and polymers are highly biocompatible and are commonly 
used for the synthesis of drug-containing nanoparticles12. Liposome surface can be functionalized readily with 
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hydrophilic polymers, such as poly(ethylene glycol) (PEG), prolonging plasma half-life and providing links to 
tumor targeting molecules13. Polymer nanoparticles show strong structural stability and are able to encapsulate 
drugs with high capacity14. Hybrid lipid-polymer nanoformulations combine the advantages of both models, 
allowing controlled drug release and enhanced bio-functionality15. Recent evidence shows that nanoformulations 
provide significant advantage to prostate cancer molecular therapies and chemotherapies allowing improvement 
in drug delivery and imaging16–18. This is particularly true for docetaxel where nanoformulations outperform 
systemic therapy19, 20. Abraxane, an albumin simple nanoparticle bound paclitaxel is currently licensed for use in 
breast, lung and pancreatic cancers.
In this study, we have tested whether encapsulation of SK1 inhibitor FTY720 (fingolimod) and docetaxel 
into nanoparticles may reduce systemic absorption and provide targeted delivery to the tumors. Core shell 
lipid-polymer hybrid nanoparticles (CSLPHNPs) with poly (lactic-co-glycolic acid) (PLGA) core and lipid layer 
containing docetaxel and FTY720 showed high serum stability, a long shelf life, a steady uptake by tumor cells 
and sustained intracellular drug release. Our data show that FTY720 (both free and in CSLPHNPs) re-sensitized 
castrate resistant prostate cancer cells and tumors to low doses of docetaxel. In mice, CSLPHNPs showed excel-
lent tumor targeting and significantly lower side effects compared to free drugs, notably reversing lymphopenia 
induced by FTY720.
Methods
Synthesis and characterization of CSLPHNPs. PLGA nanoparticle cores were prepared by emul-
sion-solvent evaporation technique21. Briefly, PLGA and docetaxel 10:1 wt% were dissolved completely in acetone. 
The entire solution was emulsified into 2% aqueous solution of 80% poly vinyl alcohol (PVA) by slow injection 
with homogenization. This mini-emulsion was then added to a 0.2% PVA solution with rapid mixing overnight to 
evaporate any residual acetone. Nanoparticle-size fraction was recovered by ultracentrifugation at 10,000, 20,000 
and 80,000 × g. A mixture of phospholipids (phosphatidylcholine and 1,2-distearoyl-sn-glycero-3-phosphoetha-
nolamine-N-[methoxy(polyethylene glycol)-2000] (18:0 PEG2000 PE)), cholesterol and FTY720 were dissolved 
in chloroform, and then a lipid film was formed in a round bottom flask under reduced pressure using a vacuum 
rotary evaporator. An aqueous solution of the smallest size fraction of PLGA nanoparticles was added to the 
film. The resulting suspension was extruded through a 200 nm membrane using a hand held extruder (Avanti, 
Alabaster) to create the lipid vesicles. The resulting hybrid lipid-polymer nanoparticles were collected by Amicon 
centrifugal filters (MWCO 100 K Da) and washed twice with distilled water.
Morphology and size measurements of CSLPHNPs. The surface morphology of the nanoparticles was 
studied using scanning electron microscopy (JEOL Ltd, UK). The CSLPHNPs were dried on an aluminum stub, 
coated with gold to obtain a uniform layer of particle and dried overnight. For dynamic light scattering (DLS) 
measurement, the size distribution and zeta potential of the nanoparticles were estimated using a Zetasizer Nano 
ZS90 (Malvern Instruments, Malvern, UK) with 90° optics and a He-Ne Laser. Nanoparticle physical structure 
was examined using freeze-fracture scanning electron microscopy (FF-SEM). The sample solution was frozen at 
−210 °C, fractured at −100 °C, sputter coated with platinum and then imaged using an FEI Nova NanoSEM 450 
FEG scanning electron microscope (FEI, Eindhoven, The Netherlands).
Liquid chromatography-tandem mass spectrometry analysis. To study the release profile of 
CSLPHNPs in vitro, nanoparticles were suspended in 1 ml of pH5/pH 7.4 buffer and were placed in an Amicon 
dialysis device (MWCO 1000 Da) suspended in 14 ml pH5/pH 7.4 buffer. After stipulated time points 2 ml ali-
quots of water was extracted and replaced with fresh water (pH 5). The dialysis device was incubated at 37 °C with 
gentle shaking. Aliquots were extracted from the incubation medium at predetermined intervals, and released 
drug was quantified by an Agilent6400 Triple Quadrupole LC-MS/MS system. Samples were applied to a Ascentis 
Express C18 reverse phase column (50 × 2.1 mm, 2.7 µm) and eluted using an 80:20 acetonitrile:isopropanol 
(ACN:IPA), water, formic acid gradient (flow rate 0.4 ml/min).
Cell lines and cell culture. Androgen insensitive prostate cancer cell lines (PC-3 and DU145) were obtained 
from DSMZ (Braunschweig, Germany). Cells were maintained in tissue culture flasks or plastic dishes in a humid-
ified atmosphere of 5% CO2 at 37 °C using RPMI 1640 supplemented with 10% heat-inactivated fetal bovine 
serum (FBS)  (Sigma‐Aldrich, UK), 50 U/ml penicillin, 50 μg/ml streptomycin and 2 mM glutamine (Sigma‐
Aldrich, UK). Cell lines were routinely verified by morphology and growth curve analysis. All experiments were 
conducted in the absence of serum. Cells were seeded to be 80% confluent by the end of treatment and were 
treated as indicated in figures’ legends. Cell lines were kept in culture for up to 30 passages.
Cell viability. Cells were grown in 96-well plates, starved, and exposed to different treatments as indicated in 
figure legends. Cellular viability was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT; 5 mg/ml) colorimetric assay as already described22.
Fluorescent microscopy and quantification of nanoparticle uptake. Prostate cancer cells were 
seeded onto 6 well plates and treated with CSLPHNPs loaded with Rhodamine B for up to 72 h. After incubation, 
the cells were washed three times with phosphate buffered saline (PBS) and fluorescent imaging was performed 
using fluorescent microscope (Carl Zeiss, USA). The fluorescent intensities in cells were quantitatively analyzed 
by ImageJ.
Sphingosine kinase 1 activity assay. SK1 assay was performed using radiolabeling as previously 
described22–24, in conditions favoring SK1 activity and inhibiting SK2 activity.
www.nature.com/scientificreports/
3Scientific RepoRts | 7: 5901  | DOI:10.1038/s41598-017-06142-x
Animal study. Animal study was performed as previously described6, 25, 26. Briefly, subcutaneous human 
prostate cancer xenografts were established in NOD scid gamma (NSG) immunodeficient male mice by sub-
cutaneous injection of 106 PC-3 cells. Three weeks after implantation, mice were randomized into treatment 
groups (n = 7/group) and treated twice a week for two weeks with: i.v. tail vein injections of: saline, 5 mg/kg 
FTY720 + 5 mg/kg docetaxel, empty CSLPHNPs, CSLPHNP (5 mg/kg FTY720 + 5 mg/kg docetaxel and labelled 
with CF488). One day after the last treatment, all mice were euthanized and blood collected for white cell count 
(WCC) measurement. Mice, tumors and individual organs were weighed and primary tumors were then pro-
cessed for analysis of SK1 activity (radiolabeling) as described above. Primary tumors, livers, spleens and kid-
neys were fixed with 4% paraformaldehyde and fluorescent images were obtained using a stereo microscope and 
quantified using ImageJ. Animal studies were performed under the Home Office license and carried out in in 
accordance with the institutional guidelines and regulations for animal welfare (University of East Anglia) and 
NC3Rs (Replacement, Reduction and Refinement) guidelines. The experiments were carried out in accordance 
with the protocols section 19B of the Home Office license and were approved by the University of East Anglia 
animal welfare committee.
Statistical analysis. Data are presented as the mean values of at least three independent experiments 
normalized to control ± standard error of the mean (SE) calculated using OriginPro8.0. Statistical significance 
between two groups was conducted by unpaired Student’s t test. Statistical significance between three or more 
groups was conducted by analysis of variance (ANOVA). p-value of < 0.05 is considered statistically significant.
Results
Nanoparticle synthesis and characterization. To synthesize CSLPHNPs we have combined emulsion 
evaporation of PLGA forming polymer core and the thin film hydration forming a lipid shell (Fig. 1). The solid 
polymeric core acts as a scaffold to encapsulate docetaxel. The lipid shell contains FTY720 and envelopes the core 
preventing internal drug leakage at plasma pH (Figure S1), while releasing the drugs at lysosomal pH (Fig. 2D).
CSLPHNPs were designed to fit the 40–200 nm size range for enhanced delivery to tumor leaky vessels accord-
ing to the theory of enhanced permeability and retention27. Scanning electron microscopy shows that CSLPHNPs 
were dispersed, with a well-defined spherical shape (Fig. 2A,B). Freeze-fracture scanning electron microscopy 
(FF-SEM) demonstrated that CSLPHNPs exhibited a core shell structure (Figure S2).
Particle sizes, polydispersity index (PDI) and zeta potentials of PLGA cores and CSLPHNPs are shown in 
Figures S3 and S4. The sizes of PLGA cores and CSLPHNPs were 88.4 ± 1.7 nm and 141.5 ± 1.2 nm, respectively 
(Figs 2C and S4). Due to the PLGA terminal carboxyl acid, PLGA nanoparticles showed an average negative sur-
face charge of −29.9 mV in PBS (Figure S4).
Drug encapsulation and release. Nanoparticle translation into clinic is limited by their stability in body 
environments. CSLPHNPs had high colloidal stability in various biological media showing no significant change 
in size and PDI (Figure S3), suggesting that they could be stored with little or no aggregation. In pure FBS and 
10% human plasma solution CSLPHNPs showed an initial ~15 nm increase in size and 0.20 increase in PDI, after 
which they maintained size and stability throughout the five-days study (Figure S3), suggesting that plasma pro-
tein binding was not a significant modifying factor, possibly due to the stable core-shell structure and the steric 
repulsion of the PEG chain because of its hydrodynamic diameter.
High drug loading and controlled release of contents are two important advantages of CSLPHNPs. The 
encapsulation of docetaxel and FTY720 in CSLPHNPs was 10% and 70%, respectively, as confirmed by liq-
uid chromatography-tandem mass spectrometry (LC-MS/MS). The low encapsulation efficiency of docetaxel 
was probably due to the size selection process of PLGA core synthesis. In vitro release profiles of FTY720 and 
docetaxel were pH dependent with a “lysosomal” pH 5 (Fig. 2D) showing a quicker release than “serum” pH 7.4 
(Figure S1). At pH 5, the release pattern of both drugs was initially similar, followed by a surge in FTY720 at 96 h 
indicating disintegration of the lipid outer layer, reaching 100% at 192 h.
Testing of nanoparticles in cell and animal models of prostate cancer. CSLPHNPs were read-
ily taken by prostate cancer cells. Fluorescent microscopy showed a rapid time-dependent accumulation of 
Figure 1. Scheme of CSLPHNPs synthesis and drug loading. Schematic representation of the preparation of 
CSLPHNPs with a multiple layer-by-layer structure. Briefly, organic solution containing PLGA and docetaxel 
was emulsified into an aqueous solution of PVA by slow injection with homogenization. After removing of any 
residual solvent, the nanoparticle-size fraction was recovered by ultracentrifugation. The smallest size fraction 
of PLGA nanoparticles aqueous solution was added to the lipid film containing phospholipids, cholesterol and 
FTY720 mixture to form CSLPHNPs. The resulting CSLPHNPs were extruded through a 200 nm membrane, 
purified and collected by Amicon centrifugal device. DTX, docetaxel.
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rhodamine B-loaded CSLPHNPs within prostate cancer cells (Figs 3A,B and S5). In PC-3 and DU145 cells the 
most effective molar ratio of FTY720:docetaxel is 5 µM:5 nM, respectively, and both drugs show additive effect 
(Figs 3C and S6). While empty CSLPHNPs exhibited no significant cytotoxicity in PC-3 cells, CSLPHNPs con-
taining same amount of FTY720/docetaxel were 15%, 27% and 6% more cytotoxic than free drugs at the 24, 48, 
and 72 h, respectively. In DU145 prostate cancer cells, CSLPHNPs induced loss of cell viability similar to free 
drugs (Figure S6). FTY720 is a known SK1 inhibitor9 and Fig. 3D shows that all FTY720 containing therapies 
including CSLPHNPs have significantly reduced SK1 activity in a similar fashion, while docetaxel alone did not 
lead to significant changes.
To investigate the in vivo effects of CSLPHNPs we used an animal model of human prostate tumors. NSG 
immunodeficient mice were inoculated with PC-3 cells. Tumors were grown for three weeks and then treated for 
two weeks with saline, free drug combination (5 mg/kg FTY720 + 5 mg/kg docetaxel), empty CSLPHNPs labelled 
with CF488 fluorophore or CSLPHNPs (5 mg/kg FTY720 + 5 mg/kg docetaxel + CF488). In the saline and the 
empty CSLPHNPs groups, tumors rapidly grew reaching 0.75 ± 0.11 g and 0.82 ± 0.12 g, respectively, by day 30, 
while free therapies and CSLPHNP have significantly reduced the tumor weight to 0.46 ± 0.07 g and 0.47 ± 0.06 g, 
respectively (Fig. 4A). Similar to in vitro studies, all treatments containing FTY720 have significantly reduced 
tumor SK1 activity (Fig. 4B). CSLPHNPs showed excellent tumor targeting capability with ~40% of CSLPHNPs 
localized in the tumor (Fig. 4C), suggesting a high selection towards unorganized tumor vessels27 with a minimal 
penetration into other tissues.
Chemotherapy-induced whole body toxicity is of utmost clinical importance as it is the key limiting factor 
to the administration of effective chemotherapy doses in cancer patients. In NSG mice, free FTY720 + docetaxel 
therapy, while having good anti-tumor efficacy (Fig. 4A) induced a 20% reduction in total body weight (Fig. 4D), 
significantly reducing liver size (Figure S7) and general mouse wellbeing. In contrast, CSLPHNPs did not affect 
body weight (Fig. 4D) or liver weight (Figure S7) demonstrating the best combination between efficacy (similar 
to free drugs) and lack of toxicity (similar to chemotherapy-free nanoparticles).
The major obstacle for FTY720 use in cancer patients is significant lymphopenia induced by this drug due 
to T-cell sequestration to lymph nodes9. Hematological assessment showed that free FTY720 has significantly 
reduced WCC after two weeks of administration (Fig. 4E). In contrast, CSLPHNPs containing FTY720 showed 
no decrease in WCC, effectively overcoming FTY720-induced lymphopenia.
Figure 2. Characterization of CSLPHNPs. Scanning electron microscopy image of (A) PLGA cores and  
(B) CSLPHNPs; 20,000/22,000X magnification (Scale bar: 1 µm). (C) Dynamic light scattering (DLS) 
measurement of the size distribution of PLGA cores-dash line, CSLPHNPs-solid line. (D) Temporal release of 
FTY720 (black squares) and docetaxel (white circles) at pH 5 was measured by liquid chromatography-tandem 
mass spectrometry (LC-MS/MS). Points, mean of three experiments performed in triplicate. Bars, SE.
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Discussion
In this paper, we addressed an important clinical problem of overcoming docetaxel chemoresistance in prostate 
cancer patients. This could be achieved through the use of molecular targeted therapy as a sensitizer and nano-
particle encapsulation to reduce toxicity and improve tumor targeting (Fig. 1).
Docetaxel on its own was not effective in the PC-3 or DU145 cells (Figs 3C and S6) therefore representing a 
model of chemoresistance. We have then combined it with an SK1 inhibitor FTY720 and demonstrated an effec-
tive chemosensitization (Figs 3C and S6). This is a new combination of a molecular sensitizer and chemotherapy 
based on our previous studies implicating SK1 in prostate cancer chemoresistance6, 26, 28. Our previous studies 
show that 20 nM docetaxel is required for successful targeting of prostate cancer cells6, therefore a dose of 5 nM 
used in this study represents a 4-fold reduction in the effective dose25.
The synthesized CSLPHNPs possessed the required properties for the tumor targeting according to 
the enhanced permeability and retention27, such as 40–200 nm size and narrow PDI (Figs 2, S1 and S3). The 
CSLPHNPs had the benefit of prolonged and lysosomal pH-specific drug release (Figs 2 and S1). In contrast to 
FTY720, only around 30% of docetaxel was released into the medium, which indicates, that most of the docetaxel 
was still under protection of the polymeric core. It is, however, possible that in cells PLGA core may be broken 
down through enzymatic degradation29, 30 leading to docetaxel release. Docetaxel has a short circulation half-life 
of ~17 hours31, FTY720 has a long half-life of 6–9 days32 and PEG functionalized liposome nanoparticles have half 
life time >5 days33. It is likely that FTY720/docetaxel encapsulation in CSLPHNPs allows stabilization of their 
intracellular release (Fig. 2D), providing an increased cytotoxic benefit.
Figure 3. In vitro assessment of CSLPHNPs. Hormone-refractory metastatic prostate cancer PC-3 cells 
were treated with free drugs or CSLPHNPs for 72 hours. (A) Fluorescent/phase contrast images of PC-3 cells 
after incubation with CSLPHNPs containing Rhodamine B. (B) CSLPHNPs uptake assessed by fluorescent 
microscopy (A) was quantified by ImageJ. (C) Cytotoxicity of CSLPHNPs was assessed using the MTT assay. 
Columns, mean of three experiments performed in triplicate. Data is expressed as mean (n = 3) ±SE. *p < 0.05 
versus control. D) PC-3 cells were treated for 48 h as indicated in figure and SK1 activity was measured by 
radiolabeling. Data is expressed as percentage relative to the control. Columns represent the mean of n = 3 ± SE. 
*p < 0.05 versus control.
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CSLPHNPs are readily taken up by prostate cancer cells and have excellent anticancer properties exceeding 
those of free drugs (Figs 3, S5 and S6). FTY720 is a known SK1 inhibitor9 and Fig. 3D shows that all FTY720 
containing therapies including CSLPHNPs have significantly reduced SK1 activity in a similar fashion, while 
docetaxel has induced an insignificant increase. Taken together our data suggest that FTY720 potentiates 
docetaxel effect through downregulation of SK1, and that the combined nanoformulation improves chemother-
apy efficacy possibly through localized release of higher concentration of both drugs inside the cells.
In vivo, 5 mg/kg FTY720 sensitized human prostate tumors grown in NSG mice to 5 mg/kg docetaxel and 
CSLPHNPs had a similar effect (Fig. 4A). Previously we have shown that at least 20 mg/kg docetaxel is required 
for successful in vivo prostate tumor treatment6, therefore our current findings represent a considerable clini-
cal advantage. CSLPHNPs had a high tumor targeting capability with a minimal penetration into other tissues 
(Fig. 4C). This is achieved through two main mechanisms. First, according to enhanced permeability/retention 
theory, nanoparticles of ~100 nM can extravasate only through “leaky” tumor vessels, but not through normal 
vasculature. Therefore, they cannot infiltrate normal tissues including liver and kidneys, which have fenestrations 
Figure 4. In vivo assessment of CSLPHNPs. NSG immune deficient mice were injected with 1 × 106 PC-3 cells 
and tumors were grown for 3 weeks. Mice were randomized in groups (n = 7) according to treatment as shown 
in figure, and treated twice a week for two weeks. CF488 fluorophore labelled CSLPHNPs were injected in the 
last treatment cycle. (A) Tumor weight at week five. (B) Intratumoral SK1 activity. (C) Fluorescent microscopy 
of mouse organs and primary tumors. Graph (on the right) indicates the levels of fluorescence in each organ 
quantified using ImageJ. (D) Relative body weight. (E) White cell count (WCC). Data is presented as mean ± SE, 
(n = 7), *p < 0.05 versus control.
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only <40 nm. Second, covering with glucosamine directs the nanoparticles to the tissues with a rapid metabolic 
turnover, including tumors.
This specific targeting has led to a significant reduction in toxicity as evidenced by increase in total body 
weight (Fig. 4D) and liver size (Figure S7) in comparison to free drugs. The major obstacle for FTY720 use in 
cancer patients is significant lymphopenia9. Hematological assessment showed that free FTY720 has significantly 
reduced WCC, while CSLPHNPs showed no decrease (Fig. 4E). When free FTY720 is administered systemically, 
it antagonizes the lymphocyte S1P receptors in the lymph nodes34. S1P levels are higher in the peripheral blood 
than in lymph nodes and serve as the driving force of lymphocyte egress to the periphery. With S1P receptors 
blocked, lymphocytes remain in the lymph nodes causing peripheral lymphopenia35–37. Here we show that encap-
sulation of FTY720 and its targeted delivery to tumor cells bypassing other tissues allows effective preservation 
of WCC in treated animals. This is the first study demonstrating a mechanism to overcome FTY720-induced 
lymphopenia, allowing its potential use in cancer patients. Our data demonstrate a clear advantage of CSLPHNPs 
over free FTY720+ docetaxel systemic therapy, specifically due to tumor targeting and reducing unwanted side 
effects.
In summary, in the current study, we have identified a new combination therapy for castrate resistant prostate 
cancer containing FTY720 and docetaxel. We have developed a CSLPHNPs formulation for delivering this new 
combination therapy in prostate cancer cells and tumors. We have shown that FTY720 re-sensitizes prostate 
cancer cells and tumors to low dose docetaxel and nanoparticle encapsulation allows a steady sustained release of 
both drugs combined with an excellent targeting capability, biocompatibility and very low toxicity in comparison 
to free therapies. An important novelty of this study is the development of a successful approach to overcome 
FTY720-induced lymphopenia, allowing its potential use in cancer patients. Collectively, these results provide the 
first evidence of improved safety and efficacy of nanoparticle encapsulated tumor targeted FTY720 and docetaxel 
combination chemotherapy for treatment of hormone-resistant prostate cancer.
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